Archives
-
Dual SMAD and Wnt Inhibition for iPSC-RGCs
2026-10-07
Chavali and colleagues reported a chemically defined, non-genetic strategy for directing induced pluripotent stem cells toward retinal ganglion cells by coordinating SMAD and canonical Wnt pathway inhibition. The resulting cultures exceeded 80% RGC purity, with Thy-1-positive enrichment approaching 95%, supporting more reproducible in vitro models of glaucoma and retinal neurodegeneration.
-
HR-LCMS/MS Reveals a New Glabrol Producer
2026-10-06
A 2026 study presents a high-resolution LC-MS/MS dereplication workflow that links bioactive plant fractions to candidate autophagy inducers. Using SH-SY5Y cells, LC3 I/II immunoblotting, chromatographic fractionation, and mass-spectrometric profiling, the authors identify Astragalus dasyanthus as a previously unreported source of glabrol-associated autophagy activity.
-
Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation
2026-10-06
Chavali and colleagues reported a chemically defined, non-genetic strategy that combines dual SMAD and canonical Wnt pathway inhibition to generate retinal ganglion cells from induced pluripotent stem cells. The study’s reported purity, enrichment, and reproducibility support iPSC-derived RGCs as a research platform for glaucoma biology, while the findings do not by themselves establish therapeutic efficacy or in vivo retinal repair.
-
MG-132 Beyond Apoptosis: A Proteostasis Lens
2026-10-05
MG-132 and Z-LLL-al are examined as interpretive tools for proteasome biology, apoptosis, and antigen-presentation research. This evidence-focused analysis connects proteostasis perturbation with findings from a T-cell-inducing COVID-19 vaccine study without overstating cross-domain conclusions.
-
Metronidazole: From Transporter Probe to Translation
2026-10-05
Metronidazole sits at the intersection of antimicrobial biology, transporter pharmacology, and microbiome research. This thought-leadership analysis examines how its reported OAT3 inhibition and established nitroimidazole identity can support translational questions—while separating product-level claims from peer-reviewed evidence and avoiding overinterpretation.
-
Multiplexed CRISPR: From Control to Translation
2026-10-04
A thought-leadership perspective on how a three-guide EGFP reference set can support rigorous thinking about multiplexed CRISPR validation, while separating mechanistic promise from evidence that is ready for translational decision-making.
-
URB597 and FAAH Signaling in Pain Research
2026-10-03
URB597, also known as KDS-4103, is a research tool used to investigate FAAH-dependent endocannabinoid signaling. This overview places its reported pharmacology alongside a 2026 mouse study of cannabidiol in inflammatory pain, emphasizing what the findings support, what they do not establish, and where translational limitations remain.
-
Multiplexed CRISPR Design: From Control to Translation
2026-10-02
Multiplexed CRISPR experiments are most valuable when they are designed as decision systems rather than simple multi-guide transfections. Using an EGFP reporter in HeLa cells as a tractable benchmark, this article connects guide-set validation, repair-outcome analysis, assay controls, and translational risk management.
-
Tofacitinib citrate: Reliable JAK Assays
2026-10-01
This scenario-driven guide shows how Tofacitinib citrate (CP-690550 citrate), SKU A4135, can support better-controlled viability, proliferation, cytokine, and inflammatory-cell experiments. It connects product handling data with concentration-aware interpretation of JAK-STAT and endothelial inflammation studies.
-
Dual Recombinase Tracing and Mouse Neo-oogenesis
2026-10-01
Xie, Zhou, and Zheng used orthogonal Cre-loxP and Dre-rox lineage tracing to test whether postnatal ovarian cells generate new oocytes in mice. Across physiological aging and busulfan-induced injury, the study detected no labeled growing oocytes or MII eggs, providing strong in vivo evidence against postnatal neo-oogenesis.
-
Asymmetric Suzuki Synthesis of an Axially Chiral Antimitotic
2026-09-30
Herrbach and co-workers reported the first application of an atropo-enantioselective Suzuki coupling to a biologically relevant antimitotic target, using chiral phosphine ligand 7a to form a nonbridged axially chiral biaryl precursor with up to 40% ee. The study provides a focused strategy for installing axial chirality before construction of the bridged biaryl framework found in rhazinilam analogues.
-
Novel Allosteric PDK4 Inhibitors in Metabolic Disease
2026-09-30
The reference study used anthraquinone-based optimization to identify compound 8c, a new allosteric pyruvate dehydrogenase kinase 4 inhibitor with nanomolar biochemical activity and preliminary in vivo efficacy. Its findings connect PDK4 inhibition with PDH activation, glucose handling, allergic inflammation, and cancer-related phenotypes while also illustrating the limitations of translating biochemical potency into therapeutic evidence.
-
Self-Assembling Peptide Nanotubes for mRNA Delivery
2026-09-29
Jung and Lim describe a structure-controlled strategy for packaging mRNA into nanotube-shaped vehicles assembled from designed peptide building blocks. The protocol links peptide synthesis and mRNA complexation with morphological, physicochemical, stability, and intracellular assays, providing a framework for evaluating filamentous carriers beyond conventional spherical nanoparticles.
-
Milk-Derived EV Uptake in Intestinal Stem Cell Models
2026-09-29
The reference study develops three porcine intestinal stem cell–based models to examine how milk-derived extracellular vesicles interact with physiologically relevant epithelium. Its central findings are that uptake depends on epithelial polarity, colon-derived stem cells show transcriptional responses to vesicles, and internalization is sensitive to endocytosis inhibition.
-
Lactate Workflows for Metabolic–Immune Research
2026-09-28
Use L-lactate as both a measurable metabolic output and a controlled perturbation to connect glycolytic flux, hypoxia, mitochondrial stress, and immune-checkpoint biology. This practical workflow emphasizes dose selection, pH controls, orthogonal readouts, and the NAT1–ENO1–lactate mechanism described in colorectal cancer research.